ClinicalTrials.gg
CompletedNCT01310166BiobankUpdated Nov 18, 2016

Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis

A Phase 4 interventional study of Fingolimod in Relapsing-remitting Multiple Sclerosis, sponsored by Novartis Pharmaceuticals. Completed at 60 sites in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-11-18.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
447
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, 1 under way, none of them phase 3. fingolimod · Multiple Sclerosis, Relapsing-Remitting.

Enrollment
5th of 19
447 · median 142
Started
2011
with 5 others
Phase 4
14 of 19
none open now
Registered
3rd of 19
by date
Lead sponsor
14 of 19
Novartis Pharmaceuticals

Among the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting, this one is the 5th largest by enrollment, is one of 6 that started in 2011, is one of 14 in phase 4, and was the 3rd registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

None of the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →

About fingolimod

fingolimod: first FDA approval 2010 (GILENYA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting as a file.
02

Study summary

The purpose of this study is to investigate which changes in immunological biomarkers under treatment with fingolimod in patients with relapsing-remitting multiple sclerosis can be detected.

03

Conditions studied

  • Relapsing-remitting Multiple Sclerosis

Keywords

  • Multiple sclerosis
  • RRMS
  • relapsing-remitting
  • fingolimod
  • biomarkers
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with relapsing forms of MS defined by 2005 revised McDonald criteria
  • Patients with Expanded Disability Status Scale (EDSS) score of 0-6.5

Exclusion criteria

Exclusion Criteria:

  • Patients with a manifestation of MS other than relapsing remitting MS
  • Patients with a history of chronic disease of the immune system other than MS such as known immunodeficiency syndrome
  • History or presence of in the last 5 years
  • Diabetic patients with moderate or severe non-proliferative diabetic retinopathy or proliferative diabetic retinopathy and uncontrolled diabetic patients
  • Diagnosis of macular edema during Screening Phase
  • Patients with active systemic bacterial, viral or fungal infections
  • Negative for varicella-zoster virus IgG antibodies at Screening
  • Patients who have been treated with cladribine, cyclophosphamide or mitoxantrone at any time
  • History of cardiovascular disorder
  • Women of child-baring potential and inadequate

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
447 participants (actual)

Study arms

  • Experimental
    Fingolimod

    Drug: Fingolimod

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline of Cluster of Differentiation (CD)4+ naive T cells (C-C Chemokine Receptor Type 7+(CCR7+CD45RA+)

    Time frame: 6 Months

  2. Change from baseline of CD8+ naïve T cells (CCR7+CD45RA+)

    Time frame: 6 months

  3. Change from baseline of CD4+ central memory T cells (CCR7+CD45RA-)

    Time frame: 6 months

  4. Change from baseline of CD8+ central memory T cells (CCR7+CD45RA-)

    Time frame: 6 months

  5. Change from baseline of CD8+ effector memory T-cells (CCR7-CD45RA-)

    Time frame: 6 months

Secondary outcomes

  1. Change from baseline of B-lymphocytes

    Time frame: 6 months

  2. Change from baseline of monocytes

    Time frame: 6 months

  3. Change from baseline of Natural Killer cells

    Time frame: 6 months

07

Study locations

60 sites
  • Novartis Investigative Site
    Ostfildern, Baden-Wuerttemberg 73760, Germany
  • Novartis Investigative Site
    Aalen, 73430, Germany
  • Novartis Investigative Site
    Abensberg, 93326, Germany
  • Novartis Investigative Site
    Altenholz-Stift, 24161, Germany
  • Novartis Investigative Site
    Alzenau, 63755, Germany
  • Novartis Investigative Site
    Andernach, 56626, Germany
  • Novartis Investigative Site
    Aschaffenburg, 63739, Germany
  • Novartis Investigative Site
    Bad Mergentheim, 97980, Germany
  • Novartis Investigative Site
    Bamberg, 96052, Germany
  • Novartis Investigative Site
    Berg, 82335, Germany
  • Novartis Investigative Site
    Berlin, 10437, Germany
  • Novartis Investigative Site
    Berlin, 10713, Germany
  • Novartis Investigative Site
    Berlin, 12165, Germany
  • Novartis Investigative Site
    Berlin, 13347, Germany
  • Novartis Investigative Site
    Bielefeld, 33611, Germany
  • Novartis Investigative Site
    Bochum, 44787, Germany
  • Novartis Investigative Site
    Bochum, 44789, Germany
  • Novartis Investigative Site
    Bochum, 44791, Germany
  • Novartis Investigative Site
    Bremen, 28755, Germany
  • Novartis Investigative Site
    Böblingen, 71032, Germany
  • Novartis Investigative Site
    Celle, 29223, Germany
  • Novartis Investigative Site
    Dortmund, 44135, Germany
  • Novartis Investigative Site
    Dresden, 01307, Germany
  • Novartis Investigative Site
    Düsseldorf, 40225, Germany
  • Novartis Investigative Site
    Erbach, 64711, Germany
  • Novartis Investigative Site
    Erlangen, 91054, Germany
  • Novartis Investigative Site
    Frankfurt, 60313, Germany
  • Novartis Investigative Site
    Fulda, 36043, Germany
  • Novartis Investigative Site
    Grevenbroich, 41515, Germany
  • Novartis Investigative Site
    Göttingen, 37073, Germany
  • Novartis Investigative Site
    Hamburg, 20249, Germany
  • Novartis Investigative Site
    Hamburg, 22083, Germany
  • Novartis Investigative Site
    Hennigsdorf, 16761, Germany
  • Novartis Investigative Site
    Jena, 07740, Germany
  • Novartis Investigative Site
    Kastellaun, 56288, Germany
  • Novartis Investigative Site
    Kiel, 24105, Germany
  • Novartis Investigative Site
    Klingenmünster, 76889, Germany
  • Novartis Investigative Site
    Krefeld, 47800, Germany
  • Novartis Investigative Site
    Lappersdorf, 93138, Germany
  • Novartis Investigative Site
    Leipzig, 04157, Germany
  • Novartis Investigative Site
    Leipzig, 04299, Germany
  • Novartis Investigative Site
    Leverkusen, 51375, Germany
  • Novartis Investigative Site
    Merzig, 66663, Germany
  • Novartis Investigative Site
    Mönchengladbach, 41239, Germany
  • Novartis Investigative Site
    München, 81829, Germany
  • Novartis Investigative Site
    Neuburg, 86633, Germany
  • Novartis Investigative Site
    Osnabrück, 49076, Germany
  • Novartis Investigative Site
    Regensburg, 93053, Germany
  • Novartis Investigative Site
    Schwendi, 88477, Germany
  • Novartis Investigative Site
    Siegen, 57076, Germany
  • Novartis Investigative Site
    Singen, 78224, Germany
  • Novartis Investigative Site
    Stade, 21682, Germany
  • Novartis Investigative Site
    Stadtroda, 07646, Germany
  • Novartis Investigative Site
    Stuttgart, 70178, Germany
  • Novartis Investigative Site
    Troisdorf, 53844, Germany
  • Novartis Investigative Site
    Tübingen, 72076, Germany
  • Novartis Investigative Site
    Ulm, 89073, Germany
  • Novartis Investigative Site
    Unterhaching, 82008, Germany
  • Novartis Investigative Site
    Wermsdorf, 04779, Germany
  • Novartis Investigative Site
    Wolfenbüttel, 38300, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2011, a primary completion of Jul 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2011
First posted
Mar 8, 2011
Start
Feb 2011
Primary completionActual
Jul 2012
CompletionActual
Jul 2012
Last update
Nov 18, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01310166
Responsible party
Sponsor
First posted
Mar 8, 2011
Start date
Feb 2011
Primary completion
Jul 2012
Completion
Jul 2012
Last update
Nov 18, 2016

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fingolimod

Start the discussion